Aurobindo Pharma

June 22 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - AUROBINDO PHARMA USA RECEIVES FTC APPROVAL TO ACQUIRE LANNETT COMPANY

• AUROBINDO PHARMA - DEAL VALUED AT $250 MILLION

Source text: ID:nnAZN4T3F3C

Further company coverage: ARBN.NS

(([email protected];))

Aurobindo Pharma has received approval from the US Federal Trade Commission for its acquisition of Lannett Company, a deal first announced in July 2025. The company said it expects the transaction to close before the end of June, a faster timeline than previously indicated. The approval removes a key regulatory hurdle for the purchase, which is being executed through Aurobindo's US subsidiary. The acquisition had been anticipated to close in early Q2 of the current fiscal year but now appears set to complete sooner. Aurobindo did not disclose the financial terms of the deal again in the filing. The Lannett business is expected to strengthen Aurobindo's presence in the US generics market.

Powered by Tijori

June 19 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - UNIT TO BUY 100% OF LANNETT COMPANY

• AUROBINDO PHARMA - OBTAINS US FTC APPROVAL FOR LANNETT ACQUISITION

• AUROBINDO PHARMA - EXPECTS LANNETT DEAL TO CLOSE BEFORE END OF JUNE 2026

Source text: ID:nBSE51F0Jx

Further company coverage: ARBN.NS

(([email protected];))

Adds FTC quote and context to paragraphs 2 and 3

June 18 (Reuters) - The U.S. Federal Trade Commission is requiring Aurobindo Pharma Limited ARBN.NS to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc., the agency said on Thursday in a statement.

The agency will require Aurobindo to divest to Quagen Pharmaceuticals an immunosuppressant prescribed to prevent organ transplant rejection, a cholesterol management drug, a drug prescribed to treat dry mouth in radiation therapy patients and a drug prescribed to reduce stomach acid.

"Aurobindo’s acquisition of Lannett would combine two of a limited number of competitors in the markets for four different generic pharmaceutical products that provide critical relief for patients, ranging from drugs used to prevent organ transplant rejection to tablets that treat dry mouth after radiation therapy," the FTC said.

(Reporting by Ryan Patrick Jones, Writing by Christian Martinez; Editing by Doina Chiacu)

(([email protected]))

** Shares of India's Aurobindo Pharma ARBN.NS down 1.3% to 1,453.8 rupees, snapping a three-session winning streak

** Stock set for biggest percentage fall since May 27, if losses hold

** US FDA on Friday flagged inspection classification of subsidiary's facility in Telangana as "official action indicated" - most serious FDA inspection classification

** Regulator concluded the inspection with 11 observations, co said

** ARBN noted it is committed to maintaining quality manufacturing standards across all facilities

** YTD, stock up 12.47%

(Reporting by Saikeerthi in Bengaluru)

(([email protected]; (+91) 8296756080))

Aurobindo Pharma's wholly owned subsidiary Eugia Pharma Specialities Ltd received an official action indicated classification from the US FDA for its Unit-III formulation manufacturing facility in Pashamylaram, Telangana. The inspection took place from January 27 to February 6, 2026, and concluded with 11 observations. The OAI designation signals that the agency found serious violations and may pursue enforcement actions such as a warning letter or import restrictions. Aurobindo said the classification would have no immediate financial or operational impact and vowed to maintain high manufacturing standards. The development follows a similar OAI classification for the company's Unit-I facility earlier this year.

Powered by Tijori

June 12 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - FDA CLASSIFIES EUGIA UNIT-III INSPECTION AS OFFICIAL ACTION INDICATED (OAI)

• AUROBINDO PHARMA - US FDA INSPECTED EUGIA UNIT-III FROM JAN 27 TO FEB 6, 2026 WITH 11 OBSERVATIONS

Source text: ID:nNSE4MQDjD

Further company coverage: ARBN.NS

(([email protected];))

June 4 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - RECEIVES FINAL US FDA APPROVAL FOR TOFACITINIB TABLETS, 5 MG AND 10 MG

Source text: ID:nNSE3hZSH6

Further company coverage: ARBN.NS

(([email protected];))

May 22 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - UNIT INCORPORATES NEW SUBSIDIARY, ARROW PHARMA PRODUCTION SAS, IN FRANCE

Source text: ID:nNSE7dLxTn

Further company coverage: ARBN.NS

(([email protected];))

May 21 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• MARCH-QUARTER CONSOL NET PAT 9.21 BILLION RUPEES

• MARCH-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 88.53 BILLION RUPEES

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];))

May 6 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - US FDA INSPECTS AUROBINDO PHARMA UNIT-VII IN TELANGANA FROM JAN 28 TO FEB 10, 2026

• AUROBINDO PHARMA - US FDA ISSUES FORM 483 WITH 9 OBSERVATIONS FOR AUROBINDO PHARMA UNIT-VII

• AUROBINDO PHARMA - UNIT RECEIVES EIR CLASSIFIED AS "VOLUNTARY ACTION INDICATED", FDA HAS CONCLUDED THAT THIS INSPECTION IS NOW CLOSED

Source text: ID:nBSE15L6dt

Further company coverage: ARBN.NS

(([email protected];))

May 1 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - UNIT SECURES HEALTH CANADA NOC FOR BEVQOLVA™ BEVACIZUMAB BIOSIMILAR

Further company coverage: ARBN.NS

(([email protected];))

April 17 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA- RECEIVES USFDA APPROVAL FOR DEXTROMETHORPHAN POLISTIREX EXTENDED-RELEASE ORAL SUSPENSION, 30 MG/5 ML (OTC)

• AUROBINDO PHARMA - PRODUCT TO BE LAUNCHED IN Q2FY27

Source text: ID:nBSE4wprRS

Further company coverage: ARBN.NS

(([email protected];))

April 15 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - THERANYM BIOLOGICS ANNOUNCES ADDITIONAL PRODUCT SCHEDULE WITH MSD

• AUROBINDO PHARMA - THERANYM TO BUILD DRUG SUBSTANCE FACILITY WITH 60 KL BIOREACTOR CAPACITY

• AUROBINDO PHARMA - THERANYM TO INVEST USD 150-175 MILLION IN MANUFACTURING FACILITY

Source text: ID:nBSEb22ZnT

Further company coverage: ARBN.NS

(([email protected];))

April 7 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - AUROBINDO PHARMA RECEIVES USFDA APPROVAL FOR DAPAGLIFLOZIN TABLETS, 5 MG AND 10 MG

• AUROBINDO PHARMA - ELIGIBLE FOR 180 DAYS SHARED GENERIC DRUG EXCLUSIVITY FOR DAPAGLIFLOZIN TABLETS

Source text: https://tinyurl.com/rdf89uy8

Further company coverage: ARBN.NS

(([email protected];))

April 6 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• CURATEQ BIOLOGICS ANNOUNCES POSITIVE PHASE 3 RESULTS FOR OMALIZUMAB BIOSIMILAR BP11

• PHASE 3 STUDY MET ALL PRIMARY ENDPOINTS IN CSU PATIENTS AT 300 MG DOSE

Source text: ID:nNSE2RrdG0

Further company coverage: ARBN.NS

(([email protected];))

March 31 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - TO CONSIDER BUYBACK OF EQUITY SHARES

Source text: ID:nBSE9sWkfw

Further company coverage: ARBN.NS

(([email protected];))

March 20 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - US FDA INSPECTS UNIT-V API FACILITY OF APITORIA PHARMA, AUROBINDO SUBSIDIARY

• AUROBINDO PHARMA - UNIT-V RECEIVES EIR CLASSIFYING FACILITY AS VAI; INSPECTION CLOSED

Source text: ID:nBSE9t0t0d

Further company coverage: ARBN.NS

(([email protected];;))

March 17 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• US FDA ISSUES FORM 483 WITH 9 OBSERVATIONS TO EUGIA PHARMA UNIT-II

• US FDA CLASSIFIES EUGIA PHARMA UNIT-II AS 'OFFICIAL ACTION INDICATED'

Source text: ID:nNSE46tRKP

Further company coverage: ARBN.NS

(([email protected];;))

March 13 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• GETS TAX DEMAND AND PENALTY OF 776.1 MILLION RUPEES EACH

Source text: ID:nBSEbyqSK8

Further company coverage: ARBN.NS

(([email protected];))

March 12 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - US FDA INSPECTS UNIT-IV OF APL HEALTHCARE LIMITED

• AUROBINDO PHARMA - FORM 483 WITH 5 OBSERVATIONS ISSUED AFTER INSPECTION

Source text: ID:nBSE8pZVp3

Further company coverage: ARBN.NS

(([email protected];;))

March 4 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• EUGIA PHARMA LAUNCHES POMALIDOMIDE CAPSULES IN US

Source text: ID:nBSE9GK9VY

Further company coverage: ARBN.NS

(([email protected];;))

Feb 27 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• COMPLETION OF US FDA INSPECTION AT UNIT I OF EUGIA PHARMA SPECIALITIES

• INSPECTION CONCLUDED WITH 4 OBSERVATIONS

Further company coverage: ARBN.NS

(([email protected];))

Feb 26 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - EUGIA PHARMA RECEIVES USFDA APPROVAL FOR EVEROLIMUS TABLETS

• AUROBINDO PHARMA - LAUNCH EXPECTED IN Q1FY27

Source text: ID:nNSEbRhvzb

Further company coverage: ARBN.NS

(([email protected];))

Feb 19 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• TAX DEPARTMENT DEMANDS RECOVERY OF REFUNDS FROM AUROBINDO

• DISPUTED AMOUNT TOTALS 1.7 BILLION RUPEES

Source text: ID:nNSE6RP0n1

Further company coverage: ARBN.NS

(([email protected];;))

** HSBC raises Aurobindo Pharma ARBN.NS PT from 1,380 rupees to 1,415 rupees, maintains "buy"

** Hike comes after US FDA approves Adquey, a non-steroid topical treatment for dermatitis

** Says Adquey has potential to become a $250-300 million brand and that ARBN needs to hire specialist salespeople

** Entry in next 6-7 months could help it capture share in a supply‑constrained category with strong prescription demand - HSBC

** ARBN up 1% at 1,157 rupees since Friday, when FDA approval was received

** 26 analysts covering ARBN have "buy" rating on avg; median PT is 1,380 rupees - data compiled by LSEG

** YTD, stock down 2.5%

(Reporting by Urvi Dugar in Bengaluru)

(([email protected]; +91 9558725583;))

Feb 13 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - FDA APPROVES ADQUEY FOR ATOPIC DERMATITIS

Source text: ID:nBSE9QTPmX

Further company coverage: ARBN.NS

(([email protected];))

** Shares of Aurobindo Pharma ARBN.NS fall around 8% to 1,106 rupees, its lowest since Oct. 31

** Stock set for its worst day since November 2022

** Pharma co posts 7.6% rise in Q3 profit to 9.1 billion rupees; consol rev rises 8.4% y/y

** Citi Research says Q3 beat was largely driven by favourable currency, continued strength in Europe

** Adds, co's flagship US generics business remains subdued

** More than 5.4 mln shares traded, 4.5x their 30-day avg

** YTD, ARBN down to ~6%

(Reporting by Brijesh Patel in Bengaluru)

(([email protected]; Ph no. +91 9590227221;))

Feb 9 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - COMPANY TO INVEST 660 MILLION RUPEES FOR 26% STAKE IN GARUDA RENEWABLES

• AUROBINDO PHARMA ONE-TIME CHARGE OF 653.3 MILLION RUPEES IN Q3 DUE TO NEW LABOUR CODES

Source text: ID:nBSE3X0Mpj

Further company coverage: ARBN.NS

(([email protected];;))